received special designations because of their potential to address serious medical conditions.
Rather than immediately approving psychedelic treatments for widespread public use, the directive focuses on reducing unnecessary delays during the scientific review process while encouraging agencies to evaluate promising evidence as efficiently as possible.continue reading …
